Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.